Enhanced expression of Epstein-Barr virus early antigens by antitubulin agents in a latently infected human lymphoblastoid cell line.
28 anticancer agents have been surveyed for Epstein-Barr virus (EBV) activating potency. Two vinca alkaloids with antitubulin activity, vinblastine (VLB) and vincristine (VCR), enhanced the expression of EBV early antigens (EA) in a latently infected human lymphoblastoid cell line (Raji), when used in combination with n-butyrate. Other antitubulin agents, colchicine, colcemid, and podophyllotoxin, had the same effect, although their effects were less than that of the potent tumor promoter, 12-O-tetradecanoyl phorbol-13-acetate (TPA).
Fujita
J
J
Yoshida
O
O
Tokuda
H
H
Sugawara
K
K
Ito
Y
Y
D000956:Antigens, Viral / Q000032:analysis*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002087:Butyrates / Q000494:pharmacology; D020148:Butyric Acid; D002460:Cell Line; D004854:Herpesvirus 4, Human / Q000187:drug effects / Q000276:immunology* / Q000502:physiology; D006801:Humans; D008214:Lymphocytes / Q000276:immunology* / Q000382:microbiology; D008870:Microtubules / Q000187:drug effects; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D050257:Tubulin Modulators; D014747:Vinblastine / Q000494:pharmacology; D014750:Vincristine / Q000494:pharmacology
D000956:Antigens, Viral; D000970:Antineoplastic Agents; D002087:Butyrates; D050257:Tubulin Modulators; D020148:Butyric Acid; D014750:Vincristine; D014747:Vinblastine; D013755:Tetradecanoylphorbol Acetate